Completed PHASE2 INTERVENTIONAL 1-arm NCT03083613

Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma

Phase II Trial of Raltitrexed and Paclitaxel as Second-line Chemotherapy for Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Sponsor: Chinese Academy of Medical Sciences

Conditions Gastric Cancer Gastroesophageal Junction Adenocarcinoma

Interventions Paclitaxel Raltitrexed

Updated 8 times since 2017 Last updated: Jan 29, 2021 Started: May 31, 2015 Primary completion: Sep 1, 2017 Completion: Dec 1, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Gastric Cancer and Gastroesophageal Junction Adenocarcinoma and is currently completed. Chinese Academy of Medical Sciences leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Oct 2023 [monthly]

Completed PHASE2
Mar 2021 — Dec 2022 [monthly]

Completed PHASE2

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Jan 2021 — Mar 2021 [monthly]

Unknown Status PHASE2
Jan 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
May 2017 — Jan 2019 [monthly]

Recruiting PHASE2

First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Medical Sciences

Data source: ChineseAMS

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China